Search

everythinglearnresearchcommunity

for

Search:↓

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

CTP-543 is generally safe for treating alopecia areata.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Gefitinib can cause rare scarring hair loss.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

The treatment combination is effective and generally safe for lung cancer.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib works well and is safe for treating alopecia areata.

Erlotinib can cause excessive eyelash growth.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Nilotinib may cause gray hair to return to its original color.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Ritlecitinib is an effective new treatment for Alopecia Areata.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.